Sugi Predict

Sugi Predict / Compounds / Ammonia Solution, Strong

Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL1151087

N.c1ccc2c(c1)CCC2

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.80
▸ MAOB P27338 4/20 0.52
▸ MAOA P21397 3/20 0.52
▸ CYP2A6 P11509 2/20 0.52
▸ HTR2C P28335 1/20 0.50
▸ MAPT P10636 1/20 0.46
▸ PNMT P11086 1/20 0.43
▸ CD44 P16070 1/20 0.43
▸ DRD4 P21917 2/20 0.43
▸ DRD2 P14416 1/20 0.42
▸ DRD1 P21728 1/20 0.42
▸ DRD5 P21918 1/20 0.42
▸ DRD3 P35462 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ BCL2L1 Q07817 1/20 0.40
▸ BAD Q92934 1/20 0.40
▸ PLAU P00749 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL6332955 1.00 TSHR (0.80) TSHRMAOBMAOACYP2A6HTR2C
Bromide SCHEMBL28831559 0.97 TSHR (0.75) TSHRMAOBMAOACYP2A6HTR2C
SCHEMBL9662 0.96 — —
SCHEMBL3057782 0.96 TSHR (0.86) TSHRMAOBMAOACYP2A6HTR2C
SCHEMBL451157 0.96 TSHR (0.86) TSHRMAOBMAOACYP2A6HTR2C
SCHEMBL29354295 0.96 — —
Ammonia Solution, Strong SCHEMBL16671421 0.94 TSHR (0.71) TSHRMAOBMAOACYP2A6HTR2C
Methane SCHEMBL19946467 0.93 TSHR (0.80) TSHRMAOBMAOACYP2A6HTR2C
SCHEMBL6277308 0.93 TSHR (0.80) TSHRMAOBMAOACYP2A6HTR2C
Water SCHEMBL7121211 0.93 TSHR (0.80) TSHRMAOBMAOACYP2A6HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114380751-B Indanamine derivatives, preparation method and application thereof 上海辉启生物医药科技有限公司 2025-03-07 — — CN claimed
CN-117946394-A Maleimide resin with low dielectric and high toughness indane condensation configuration, and preparation method and application thereof 四川东材科技集团股份有限公司 2024-04-30 — — CN claimed
CN-114380751-A Indane amine derivatives, preparation method and application thereof 上海辉启生物医药科技有限公司 2022-04-22 — — CN claimed
CN-114315736-A Indane amine derivatives, preparation method and application thereof 甫康（上海）健康科技有限责任公司 2022-04-12 — — CN claimed
EP-3565808-B1 COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS ARDELYX INC (US) 2026-03-04 — — EP disclosed
US-12281103-B2 Compounds useful for treating gastrointestinal tract disorders ARDELYX, INC. (US) 2025-04-22 — — US disclosed
US-20240317719-A1 COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2024-09-26 — — US disclosed
CN-117946394-A Maleimide resin with low dielectric and high toughness indane condensation configuration, and preparation method and application thereof 四川东材科技集团股份有限公司 2024-04-30 — — CN disclosed
US-20220306610-A1 COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2022-09-29 — — US disclosed
CN-114380751-A Indane amine derivatives, preparation method and application thereof 上海辉启生物医药科技有限公司 2022-04-22 — — CN disclosed
CN-114380751-A Indane amine derivatives, preparation method and application thereof 上海辉启生物医药科技有限公司 2022-04-22 — — CN disclosed
CN-114315736-A Indane amine derivatives, preparation method and application thereof 甫康（上海）健康科技有限责任公司 2022-04-12 — — CN disclosed
US-7884244-B2 Therapeutic fluoroethylcyano guanidines ALLERGAN, INC. (US) 2011-02-08 — — US disclosed
CN-101827818-A 9, 10-acridan as an antioxidant CHEMTURA CORP 2010-09-08 — — CN disclosed
CN-101801912-A Diaromatic amine derivatives as antioxidants CHEMTURA CORP 2010-08-11 — — CN disclosed
US-7598417-B2 Analgesics; muscular disorders; diarrhea ALLERGAN, INC. (US) 2009-10-06 — — US disclosed
US-20080255230-A1 THERAPEUTIC FLUOROETHYLCYANO GUANIDINES ALLERGAN, INC. 2008-10-16 — — US disclosed
US-20080255239-A1 SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS ALLERGAN, INC. 2008-10-16 — — US disclosed
WO-1989006125-A1 4-ARALKYL-5-SUBSTITUTED-1,2,4-TRIAZOLE-5-THIOLS SMITHKLINE BECKMAN CORPORATION (US) 1989-07-13 — — WO disclosed
EP-0323737-A1 4-Aralkyl-5-substituted-1,2,4-triazole-5-thiols SMITHKLINE BEECHAM CORPORATION (US) 1989-07-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255230-A1 THERAPEUTIC FLUOROETHYLCYANO GUANIDINES PDE3A, PDE2A, PDE3B TSHR 2803/4885MAOB 137/4885MAOA 115/4885
US-20220306610-A1 COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS SLC10A2, FABP2, SLC10A1 TSHR 579/4885MAOB 3161/4885MAOA 3842/4885
US-12281103-B2 Compounds useful for treating gastrointestinal tract disorders SLC10A2, FABP2, SLC10A1 TSHR 579/4885MAOB 3161/4885MAOA 3842/4885
US-20080255239-A1 SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS ADRB2, ADRA2A, ADRA2C TSHR 2066/4885MAOB 653/4885MAOA 251/4885
US-20240317719-A1 COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS SLC10A2, FABP2, SLC10A1 TSHR 579/4885MAOB 3161/4885MAOA 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.